|
Aug 5
|
New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference
|
|
Jul 29
|
New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain
|
|
Jul 24
|
AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option
|
|
Jul 24
|
AlzeCure's Rights Issue Oversubscribed According to Preliminary Results
|
|
Jul 23
|
3 European Penny Stocks With Market Caps Under €30M
|
|
Jul 21
|
AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference
|
|
Jul 16
|
AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue
|
|
Jul 15
|
AlzeCure's Pain Project ACD440 Granted Orphan Drug Status in the US by the FDA
|
|
Apr 9
|
Notice to Annual General Meeting in AlzeCure Pharma AB
|
|
Apr 7
|
New Data Bolstering the Anti-inflammatory Effect of NeuroRestore ACD856 Presented at Alzheimer's Conference
|
|
Feb 24
|
New Article Showing the Unique Mechanism of Action Behind Alzstatin as an Alzheimer's Treatment
|
|
Feb 17
|
AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease
|
|
Jan 21
|
AlzeCure Receives Abstract Acceptance at Alzheimer’s Congress AD/PD 2025 on NeuroRestore ACD856
|